Clinical Trials

A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)


Study ID
CYNK-001-AML-001

NCT Number
NCT04310592 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0772

Principle Investigator
Dr. McCloskey II, James K.

Phase
I

Sponsor
Celularity


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now